This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

As OpenAI trial looms, Musk's new proposed remedies draw US judge's skepticism

By Mike Swift and Amy Miller ( April 17, 2026, 22:42 GMT | Insight) -- Just over a week before Elon Musk's trial against OpenAI over its for-profit conversion, a federal judge expressed skepticism Friday about whether Musk will be able to seek newly expanded remedy claims including removing Sam Altman as CEO and unwinding OpenAI’s for-profit conversion and restructuring aided by Microsoft, the second defendant in the trial.Just over a week before the start of Elon Musk's trial against OpenAI over its for-profit conversion, it remained unclear Friday whether Musk will be able to seek expanded remedies including the removal of Sam Altman as CEO and Greg Brockman as president....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections